Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Delcath Systems Inc - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS
Ticker
Exchange
SIC #
Website
Latest Ticker
DCTH
Nasdaq
3841
http://delcath.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Delcath Systems Inc
Delcath Systems Stock Jumps After Data Update From Eye Cancer Trials At ASCO Meeting
- Jun 7th, 2022 11:06 am
Positive Initial Results from CHOPIN Phase 1b Trial, FOCUS Trial Update and QoL Study Presented at the 2022 ASCO Annual Meeting
- Jun 6th, 2022 8:15 pm
Delcath Systems Reports First Quarter 2022 Results and Provides Business Update
- May 10th, 2022 11:30 am
Delcath Announces Poster Presentation at the 2022 ASCO Annual Meeting
- May 9th, 2022 12:30 pm
Is Delcath Systems (NASDAQ:DCTH) Using Too Much Debt?
- May 2nd, 2022 7:02 pm
Delcath Systems to Host First Quarter 2022 Results
- Apr 28th, 2022 1:00 pm
Delcath Systems to Participate in the Canaccord Genuity Horizons in Oncology Conference
- Apr 8th, 2022 1:00 pm
Delcath Systems to Participate in the Lytham Partners Spring 2022 Investor Conference
- Mar 29th, 2022 1:00 pm
Delcath Systems Reports Fourth Quarter and Full-Year 2021 Results and Provides Business Update
- Mar 25th, 2022 11:30 am
Delcath Systems to Host Fourth Quarter and Full Year 2021 Results
- Mar 15th, 2022 8:30 pm
Delcath Systems to Present at the 34th Annual Roth Conference
- Mar 10th, 2022 2:00 pm
Delcath Systems Achieves Medical Device Regulation Certification for CHEMOSAT® in Europe
- Mar 2nd, 2022 9:01 pm
Delcath Systems Announces Move to a Direct Sales & Marketing Model for CHEMOSAT®
- Feb 22nd, 2022 2:00 pm
Delcath Systems to Present at Upcoming Virtual Investor Conferences
- Feb 10th, 2022 9:30 pm
Delcath Appoints Anthony Dias as its new Vice President of Finance; Inducement Grant Reported
- Feb 7th, 2022 9:01 pm
Delcath's Chemosat Hepatic Delivery System Shows Overall Response Rate Of 60.5% In Eye Cancer That Spreads To Liver
- Feb 4th, 2022 2:00 pm
Results of Single Center Study on Delcath’s CHEMOSAT® Hepatic Delivery System Published in Melanoma Research
- Feb 3rd, 2022 9:30 pm
David Hoffman Joins Delcath Systems, Inc. as General Counsel and Corporate Secretary
- Jan 25th, 2022 9:01 pm
Delcath Systems to Present at the H.C. Wainwright BioConnect Virtual Investor Conference on January 10, 2022
- Jan 7th, 2022 2:00 pm
Delcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato™ in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data Analysis
- Dec 2nd, 2021 1:00 pm
Scroll